Author
Listed:
- Seamus Kent
(University of Oxford)
- Frauke Becker
(University of Oxford)
- Talitha Feenstra
(National Institute for Public Health and the Environment (RIVM), Centre for Nutrition, Prevention and Health Services Research
University of Groningen, Faculty of Science and Engineering, Groningen Research Institute of Pharmacy)
- An Tran-Duy
(The University of Melbourne)
- Iryna Schlackow
(University of Oxford)
- Michelle Tew
(The University of Melbourne)
- Ping Zhang
(Centres for Disease Control and Prevention)
- Wen Ye
(University of Michigan)
- Shi Lizheng
(Tulane University)
- William Herman
(University of Michigan)
- Phil McEwan
(Swansea University)
- Wendelin Schramm
(GECKO Institute, Heilbronn University)
- Alastair Gray
(University of Oxford)
- Jose Leal
(University of Oxford)
- Mark Lamotte
(IQVIA)
- Michael Willis
(The Swedish Institute for Health Economics)
- Andrew J Palmer
(The University of Melbourne
Menzies Institute for Medical Research, The University of Tasmania)
- Philip Clarke
(University of Oxford
The University of Melbourne)
Abstract
Transparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a potential method for promoting transparency, while also reducing the duplication of effort. An important network initiative is the ongoing construction of a diabetes model registry (https://www.mthooddiabeteschallenge.com). Following the 2012 International Society for Pharmacoeconomics and Outcomes Research and the Society of Medical Decision Making (ISPOR-SMDM) guidelines, we recommend that modelling groups provide technical and non-technical documentation sufficient to enable model reproduction, but not necessarily provide the model code. We also request that modelling groups upload documentation on the methods and outcomes of validation efforts, and run reference case simulations so that model outcomes can be compared. In this paper, we discuss conflicting definitions of transparency in health economic modelling, and describe the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes Challenge Network, its objectives and potential further developments, and highlight the challenges in its construction and maintenance. The support of key stakeholders such as decision-making bodies and journals is key to ensuring the success of this and other registries. In the absence of public funding, the development of a network of modellers is of huge value in enhancing transparency, whether through registries or other means.
Suggested Citation
Seamus Kent & Frauke Becker & Talitha Feenstra & An Tran-Duy & Iryna Schlackow & Michelle Tew & Ping Zhang & Wen Ye & Shi Lizheng & William Herman & Phil McEwan & Wendelin Schramm & Alastair Gray & Jo, 2019.
"The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood,"
PharmacoEconomics, Springer, vol. 37(11), pages 1305-1312, November.
Handle:
RePEc:spr:pharme:v:37:y:2019:i:11:d:10.1007_s40273-019-00825-1
DOI: 10.1007/s40273-019-00825-1
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Pierre Johansen & Daniel Howard & Ryan Bishop & Søren Ilsøe Moreno & Kristine Buchholtz, 2020.
"Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements,"
PharmacoEconomics, Springer, vol. 38(5), pages 485-497, May.
- Paul Tappenden & J. Jaime Caro, 2019.
"Improving Transparency in Decision Models: Current Issues and Potential Solutions,"
PharmacoEconomics, Springer, vol. 37(11), pages 1303-1304, November.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:37:y:2019:i:11:d:10.1007_s40273-019-00825-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.